We first performed a pre-dose blood withdrawal at 17 days post-PBMC injection to confirm successful immune reconstitution of human CD45+ (hCD45) cells in these GVHD-bearing mice before we administered human MSCLC, MSCHC or saline. The gene discussed is PTPRC; the disease is graft versus host disease.